COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,544 Articles (22,881 medRxiv, 8,663 bioRxiv)

Most recent first Previous |  Page 996: Articles 9951-9960  | Next

A longitudinal seroconversion panel shows anti-SARS-CoV-2 antibody levels up to 6.5 months after vaccination with mRNA-1273 (Moderna)
Belda, F., Mora, O., Christie, R., Crowley, M.
10.1101/2022.01.25.22269762 — Posted: 2022-01-28
SARS-CoV-2 seroprevalence in children, parents and school personnel from June 2020 to April 2021: cohort study of 55 schools in Switzerland
Ulyte, A., Haile, S. R., Blankenberger, J., Radtke, T., Puhan, M. A., Kriemler, S.
10.1101/2022.01.25.22269827 — Posted: 2022-01-28
Breadth of SARS-CoV-2 Neutralization and Protection Induced by a Nanoparticle Vaccine
Li, D., Martinez, D. R., Schäfer, A., Chen, H., Barr, M., Sutherland, L. L., Lee, E., Parks, R., Mielke, D., Edwards, W., Newman, A., Bock, K. W., Minai, M., Nagata, B. M., Gagne, M., Douek, D., DeMarco, C. T., Denny, T. N., Oguin, T. H., Rountree, W., Wang, Y., Mansouri, K., Edwards, R. J., Ferrari, G., Sempowski, G. D., Eaton, A., Tang, J., Cain, D. W., Santra, S., Pardi, N., Weissman, D., Tomai, M., Fox, C., Moore, I. N., Andersen, H., Lewis, M. G., Golding, H., Khurana, S., Seder, R., Baric, R. S., Montefiori, D. C., Saunders, K. O., Haynes, B. F.
10.1101/2022.01.26.477915 — Posted: 2022-01-28
Positive attribute framing increases COVID-19 booster vaccine intention for unfamiliar vaccines
Barnes, K., Colagiuri, B.
10.1101/2022.01.25.22269855 — Posted: 2022-01-28
Effectiveness of a SARS-CoV-2 mRNA vaccine booster dose for prevention of infection, hospitalization or death in two nation-wide nursing home systems
McConeghy, K. W., Bardenheier, B., Huang, A. W., White, E. M., Feifer, R. A., Blackman, C., Santostefano, C. M., Lee, Y., DeVone, F., Halladay, C. W., Rudolph, J. L., Zullo, A. R., Mor, V., Gravenstein, S.
10.1101/2022.01.25.22269843 — Posted: 2022-01-28
The inactivated NDV-HXP-S COVID-19 vaccine induces a significantly higher ratio of neutralizing to non-neutralizing antibodies in humans as compared to mRNA vaccines
Carreno, J. M., Raskin, A., Singh, G., Tcheou, J., Kawabata, H., Gleason, C., Srivastava, K., Vigdorovich, V., Dambrauskas, N., Gupta, S. L., Gonzalez, I., Martinez, J. L., Slamanig, S., Sather, D. N., Raghunandan, R., Wirachwong, P., Muangnoicharoen, S., Pitisuttithum, P., Wrammert, J., Suthar, M. S., Sun, W., Palese, P., Garcia-Sastre, A., Simon, V., Krammer, F.
10.1101/2022.01.25.22269808 — Posted: 2022-01-28
How dangerous is omicron and how effective are vaccinations?
Nesteruk, I., Rodionov, O.
10.1101/2022.01.27.22269909 — Posted: 2022-01-28
Cardiovascular, respiratory and functional effects of tele-supervised home-based exercise training in individuals recovering from COVID-19 hospitalization: A randomized clinical trial
Amaral, V. T. d., Viana, A. A., Heubel, A. D., Linares, S. N., Martinelli, B., Witzler, P. H. C., Oliveira, G. Y. O. d., Zanini, G. d. S., Silva, A. B., Mendes, R. G., Ciolac, E. G.
10.1101/2022.01.24.22269745 — Posted: 2022-01-28
COVID-19 vaccine attitude and its predictors among people living with chronic health conditions in Ibadan, Nigeria
Ojewale, L. Y., Afolabi, R. F., Ogunniyi, A.
10.1101/2022.01.27.22269947 — Posted: 2022-01-28
Open science policies of medical and health sciences journals before and during the COVID-19 pandemic: a repeat cross-sectional study
Gardener, A. D., Hicks, E. J., Jacklin, C., Tan, G., Cashin, A. G., Lee, H., Nunan, D., Toomey, E. C., Richards, G. C.
10.1101/2022.01.26.22269868 — Posted: 2022-01-28

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).